Join to view full profile
1100 9th AveVirginia Mason Med Ctr, Div Hem/OncSeattle, WA 98101
Phone+1 206-223-6600
Dr. Picozzi is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1981 - 1982
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1978 - 1981
Stanford University School of MedicineClass of 1978
Certifications & Licensure
CA State Medical License 1981 - Present
WA State Medical License 1985 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Powerchart, Cerner Healthe and Cerner Patient Portal, Cerner Corporation, 2012, 2014, 2016
- CMS Meaningful Use Stage 1 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2012, 2014, 2016
- CMS Meaningful Use Stage 1 Certification HealthSentry, Cerner Corporation, 2012, 2014, 2016
Clinical Trials
- Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
- Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
- A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Publications & Presentations
PubMed
- Estimating the cost-effectiveness of tumor treating fields for locally advanced pancreatic cancer patients.Gregory F Guzauskas, Vincent Picozzi, Jorge Fernando Niño de Rivera Guzman, Bruce C M Wang
Journal of Medical Economics. 2026-12-01 - 26 citationsTumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.Hani M Babiker, Vincent Picozzi, Sreenivasa R Chandana, Bohuslav Melichar, Anup Kasi
Journal of Clinical Oncology. 2025-07-20 - 3 citationsPancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study.Vincent J Picozzi, Margaret T Mandelson, Anas Najjar, Moming Li, Diala E Harb
The Oncologist. 2025-04-04
Journal Articles
- Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor InitiativeSameh Mikhail, Vincent J Picozzi, Clinical Cancer Research
Lectures
- Prognostic value (PV) of pathologic response (PR) to neoadjuvant chemotherapy (NC) alone in resected pancreatic cancer (PDAC): Initial analysis.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 cl...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
FDA Approves Tumor-Treating Fields Device for Pancreatic CancerFebruary 12th, 2026- TTFields plus Chemo Deemed New Paradigm for Locally Advanced Pancreatic AdenocarcinomaAugust 14th, 2025
- Research Spotlight by Dr. Anna Berkenblit: June 2025June 23rd, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: